Key Stats for Johnson & Johnson Stock
- Current Price: $254 (July 17, 2026)
- Q2 2026 Revenue: $25.31B, +6.6% YoY, beat Street estimate by roughly 1%
- Q2 2026 Adjusted EPS: $2.90, +4.7% YoY, beat Street’s $2.85 estimate by roughly 2%
- Q2 2026 EBIT Margin: 33%
- FY2026 Adjusted Operational EPS Guidance (raised): $11.50 to $11.65, up $0.18 at the midpoint
- FY2026 Operational Sales Growth Guidance (raised): 6.5% to 7.1%
- TIKR Model Price Target: $466
- Implied Upside: 87%
JNJ Stock Beats and Raises as New Launches Outrun the STELARA Drag
Johnson & Johnson (JNJ), the diversified healthcare company spanning prescription drugs and medical devices, posted adjusted earnings per share of $2.90 against a $2.85 Street estimate following its Q2 2026 earnings call on July 15, with Johnson & Johnson stock trading near $254.
The beat was driven by 6.8% operational sales growth in the Innovative Medicine drug segment to $16.4 billion, a result management achieved despite absorbing a 760 basis point revenue headwind from biosimilar erosion of STELARA, the company’s former blockbuster immunology drug.
Worldwide revenue reached $25.31 billion, up 6.6% year over year and 0.99% above the Street’s $25.06 billion estimate, while the newer immunology drug TREMFYA posted its first $2 billion quarter on sales growth of 71%.
Joaquin Duato, Chairman and CEO, stated on the Q2 2026 earnings call that “we said 2026 would be a year of accelerated growth and impact for JNJ ,” tying the remark directly to the quarter’s beat and the subsequent guidance raise.
Management raised full year adjusted operational EPS guidance to a range of $11.50 to $11.65, up $0.18 at the midpoint, and lifted operational sales growth guidance to 6.5% to 7.1%, while Duato reiterated a target of double digit growth for Johnson & Johnson by the end of the decade as new drugs ICOTYDE, INLEXZO and RYBREVANT continue scaling.
The MedTech device segment grew a slower 3.6% as cardiovascular sales rose just 3.1%, weighed down by a 400 basis point China inventory headwind in electrophysiology and a 2% decline in Abiomed heart pump sales after physicians grew more selective following a neutral UK clinical trial.
Johnson & Johnson also disclosed plans to acquire FireFly Bio, adding a KRAS-targeting oncology platform expected to close in the third quarter, part of a stated push to become the top oncology company by 2030 with more than $50 billion in sales.
The ICOTYDE psoriasis launch showed early traction with 11,000 patients started on therapy across 6,000 prescribers and more than 50% commercial payer coverage secured within 90 days of launch, a pace Jennifer Taubert, Executive Vice President of Innovative Medicine, called “a little bit ahead of our projections.”
TIKR Values Johnson & Johnson Stock at $466, Pricing In the Launch Transition
TIKR’s mid case model values Johnson & Johnson at $466 by December 2034, implying 87% total return from the current price of $254, or 8% annualized.
That return profile puts Johnson & Johnson stock ahead of the slow, single-digit total return path investors typically expect from a mega cap pharmaceutical name carrying a defensive reputation.
The model prices in Innovative Medicine’s 6.8% growth and the STELARA replacement cycle already underway: TREMFYA’s first $2 billion quarter, ICOTYDE’s 11,000 patients started and INLEXZO’s 75% quarter over quarter uptick in new insertions are the specific drivers TIKR’s base case assumes will keep compounding as guidance moves higher.
Should You Invest in Johnson & Johnson?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Johnson & Johnson stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Johnson & Johnson alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze JNJ stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
